Biocartis Announces Nine Idylla™ Studies Published at AMP 2022 Annual Meeting

Last updated: 15th November, 2022

Among the studies published, four studies on the Idylla™ GeneFusion Assay highlighted the strengths of Idylla™ testing including high accuracyease-of-use and rapid time-to-results.

Furthermore, one study performed with the new SeptiCyte RAPID® EDTA blood compatible cartridges4 on the Idylla™ platform, developed in collaboration with Immunexpress, concluded that the addition of the widely used EDTA blood tube as a validated sample type has the potential to greatly enhance the clinical utility of this new near-patient sepsis diagnostic.

The other studies related to the use of the Idylla™ EGFR Assay, the Idylla™ MSI Assay and the Idylla™ NRAS-BRAF Assay

These studies highlight the benefit of Idylla™ testing versus testing on more complex and slower technologies such as Next Generation Sequencing. With Idylla™, the time-to-result of diagnostic testing is decreased, indicating the suitability of Idylla™ testing for rapid molecular testing.

Page

Abstract ID

Title

53

ID007

Multi-Site Validation of EDTA Blood as a Sample Type for SeptiCyte RAPID CE-IVD, a Near-Patient Diagnostic Test for Sepsis on the Biocartis Idylla System

79

I012

Evaluation of RET Fusion Identification by the Idylla GeneFusion Assay

90

ST006

Clinical Validation of an Automated Gene Fusion Assay for Non-Small Cell Lung Carcinoma

90

ST008

Development and Validation of an Ultra-Rapid Assay for Detection of NTRK1/2/3 Fusions

92

ST013

Validation of Idylla EGFR Assay for Rapid Detection of EGFR Mutations in Patients’ FFPE Tissues

94

ST016

Performance of MSI Testing by the Automated Rapid Idylla Assay in Comparison with the Promega Assay in MMR-Deficient Endometrial Carcinomas

95

ST019

BioCartis Idylla Testing for EGFR Mutations in Lung Adenocarcinoma Reveals Low Clinical Sensitivity for Detecting Exon 20 Insertion Alterations

100

ST034

Rapid Assessment of Kinase Gene Fusions Using the Idylla GeneFusion Assay in Lung Adenocarcinoma

103

ST041

Idylla BRAF and NRAS

 

Idylla™ study abstracts selected for AMP 2022

Download PDF >



Request a Quote

Request Quote

Go BackGo Back
Top